Image

FDA & Cancer - Part 2: Benefits First

Length: [6:54]

In a rare public interview, three of FDA's cancer drug reviewers say their clinical practice provides the incentives to approve new drugs, but that they must be vigilant to approve therapies that provide real benefits.

More Videos